不同类型的表皮生长因子受体酪氨酸激酶抑制剂在肺癌患者使用抗 PD-1 抗体之前和/或之后的不同发生率与间质性肺病相关。
Different incidence of interstitial lung disease according to different kinds of EGFR-tyrosine kinase inhibitors administered immediately before and/or after anti-PD-1 antibodies in lung cancer.
机构信息
Department of Respiratory Medicine Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan.
出版信息
Thorac Cancer. 2019 Apr;10(4):975-979. doi: 10.1111/1759-7714.13039. Epub 2019 Mar 12.
BACKGROUND
The aim of our study was to retrospectively assess the incidence of interstitial lung disease (ILD) related to EGFR-tyrosine kinase inhibitor (TKI) treatment immediately before and/or after the administration of a PD-1 antibody.
METHODS
We analyzed the data of 26 patients who underwent treatment with EGFR-TKIs immediately before and/or after the administration of an anti-PD-1 antibody.
RESULTS
Four out of the 26 patients developed ILD during EGFR-TKI treatment: three patients during the administration of osimertinib immediately after, and one during afatinib immediately before treatment with an anti-PD-1 antibody. Three of 12 patients who underwent EGFR-TKI therapy immediately after anti-PD-1 antibody treatment experienced osimertinib-induced ILD. ILD was not observed in the five patients administered an anti-PD-1 antibody followed by first or second-generation EGFR-TKIs.
CONCLUSION
ILD was observed in the treatment sequence of an anti-PD-1 antibody followed by osimertinib, but not with first or second-generation EGFR-TKIs.
背景
本研究旨在回顾性评估 PD-1 抗体治疗前后 EGFR-酪氨酸激酶抑制剂（TKI）治疗相关间质性肺病（ILD）的发生率。
方法
我们分析了 26 例接受 EGFR-TKI 治疗并在 PD-1 抗体治疗前后接受治疗的患者的数据。
结果
26 例患者中有 4 例在 EGFR-TKI 治疗期间发生 ILD：3 例在奥希替尼治疗后立即发生，1 例在阿法替尼治疗前立即发生 PD-1 抗体。12 例接受 EGFR-TKI 治疗后立即接受抗 PD-1 抗体治疗的患者中有 3 例发生奥希替尼诱导的 ILD。5 例接受抗 PD-1 抗体治疗后接受第一代或第二代 EGFR-TKI 治疗的患者未观察到 ILD。
结论
在抗 PD-1 抗体治疗后序贯奥希替尼治疗时观察到 ILD，但在第一代或第二代 EGFR-TKI 治疗时未观察到。
Zotero 插件